Timothy Walbert - Horizon Pharma Chairman, CEO and Pres
Chairman
Mr. Timothy P. Walbert is Chairman of the Board, President, Chief Executive Officer of the Company. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, Mr. Walbert served as executive vice president, commercial operations of NeoPharm, Inc., a public biopharmaceutical company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multiindication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. Mr. Walbert also serves as chairman of the board of directors of Egalet Corporationrationration, a public pharmaceutical company. Mr. Walbert sits on the board of directors of the Illinois Biotechnology Innovation Organization, the Biotechnology Innovation Organization, World Business Chicago and the Greater Chicago Arthritis Foundation. Mr. Walbert is also a member of the Illinois Innovation Council. Mr. Walbert previously served on the board of directors of Raptor Pharmaceutical Corporationration, a public biopharmaceutical company, from 2010 to 2014 XOMA Corporationrationration, a public biotechnology company, from 2010 to 2017 and Sucampo Pharmaceuticals, Inc., a public biopharmaceutical company, from March 2016 to February 2018 since 2010.
| Age | 56 |
| Tenure | 15 years |
| Phone | 353 1 772 2100 |
| Web | https://www.horizontherapeutics.com |
Timothy Walbert Latest Insider Activity
Tracking and analyzing the buying and selling activities of Timothy Walbert against Horizon Pharma stock is an integral part of due diligence when investing in Horizon Pharma. Timothy Walbert insider activity provides valuable insight into whether Horizon Pharma is net buyers or sellers over its current business cycle. Note, Horizon Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Horizon Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Timothy Walbert over a year ago Acquisition by Timothy Walbert of 7000 shares of XOMA Corp subject to Rule 16b-3 | ||
Timothy Walbert over a year ago Exercise or conversion by Timothy Walbert of 2800 shares of XOMA Corp subject to Rule 16b-3 |
Horizon Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0444 % which means that it generated a profit of $0.0444 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0854 %, meaning that it created $0.0854 on every $100 dollars invested by stockholders. Horizon Pharma's management efficiency ratios could be used to measure how well Horizon Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Horizon Pharma PLC currently holds 2.56 B in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Horizon Pharma PLC has a current ratio of 3.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Horizon Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Daniel Vasella | Novartis AG ADR | 65 | |
| Robert Bradway | Amgen Inc | 62 | |
| Jennifer Taubert | Johnson Johnson | 61 | |
| Alex Gorsky | Johnson Johnson | 64 | |
| Robert JD | Merck Company | 58 | |
| Carlos Alban | AbbVie Inc | 55 | |
| Paulus Stoffels | Johnson Johnson | 57 | |
| Joerg Reinhardt | Novartis AG ADR | 65 | |
| Robert Michael | AbbVie Inc | 55 | |
| Daniel ODay | Gilead Sciences | 60 | |
| Giovanni Caforio | Bristol Myers Squibb | 56 | |
| Alex Krauer | Novartis AG ADR | 69 | |
| Richard Gonzalez | AbbVie Inc | 71 | |
| Leif Johansson | AstraZeneca PLC ADR | 68 | |
| Ashley McEvoy | Johnson Johnson | 50 | |
| Kenneth Frazier | Merck Company | 67 | |
| Enrico Vanni | Novartis AG ADR | 70 | |
| Thibaut Mongon | Johnson Johnson | 51 | |
| Joaquin Duato | Johnson Johnson | 62 | |
Management Performance
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 |
Horizon Pharma PLC Leadership Team
Elected by the shareholders, the Horizon Pharma's board of directors comprises two types of representatives: Horizon Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Horizon. The board's role is to monitor Horizon Pharma's management team and ensure that shareholders' interests are well served. Horizon Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Horizon Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jane Gonnerman, Office Staff | ||
| Sean JD, Exec Counsel | ||
| Timothy Walbert, Chairman, CEO and Pres | ||
| Tina Ventura, Senior Vice President Investor Relations | ||
| Patrick McIlvenny, VP Officer | ||
| Paul Hoelscher, CFO and Executive VP of Fin. | ||
| FACP FACP, Ex Officer | ||
| Andy Pasternak, Ex Officer | ||
| Aaron Cox, Exec CFO | ||
| Geoffrey Curtis, Senior Vice President - Corporate Communications |
Horizon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Horizon Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 26.87 B | |||
| Shares Outstanding | 229 M | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 98.82 % | |||
| Number Of Shares Shorted | 7.1 M | |||
| Price To Earning | 32.55 X |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |